In vitro release of dexmedetomidine from silica xerogel monoliths: effect of sol-gel synthesis parameters

2001 ◽  
Vol 221 (1-2) ◽  
pp. 107-114 ◽  
Author(s):  
Pirjo Kortesuo ◽  
Manja Ahola ◽  
Minna Kangas ◽  
Antti Yli-Urpo ◽  
Juha Kiesvaara ◽  
...  
1999 ◽  
Vol 25 (8) ◽  
pp. 955-959 ◽  
Author(s):  
Manja Ahola ◽  
Pirjo Kortesuo ◽  
Ilkka Kangasniemi ◽  
Juha Kiesvaara ◽  
Antti Yli-Urpo

2005 ◽  
Vol 284-286 ◽  
pp. 423-426 ◽  
Author(s):  
Y. Kim ◽  
B.G. Song ◽  
Soo Ryong Kim ◽  
Kwang Jin Kim

Porous hydroxyapatite coated with mesoporous silica has been utilized as the matrix for controlled drug delivery. TEM observation confirms the pore size of mesoporous silica scatters about 50 Å. Porous hydroxyapatite was coated with mesoporous silica via sol-gel process. Ibuprofen and was loaded into the pores of mesoporous silica, and controlled release profiles were studied by soaking the samples in a simulated body fluid using a UV-VIS spectrophotometer.


2016 ◽  
Vol 12 (4) ◽  
pp. 4365-4373
Author(s):  
M. González Hurtado ◽  
J. Rieumont Briones ◽  
Laura. M. Castro González ◽  
E. Ortiz- Islas ◽  
Inti Zumeta- Dube

In this paper is reported the “in vitro” release kinetic studies of antiepileptic drugs released from an inorganic, titanium oxide (TiO2) porous matrix. In order to determine the drug release mechanism, the experimental values were fitted to different mathematical models: zero-order, firs-order, Higuchi, Hixson-Crowel and Peppas. TiO2 was prepared by the sol-gel method adding valproic acid (VPA) or phenytoine (DHP) during the titanium n-butoxide hydrolysis step. The drug-TiO2 systems were observed by scanning electron microscopy. The “in vitro” release experiments were performed at laboratory scale following the United States Pharmacopeia (USP) standards. The obtained materials have a morphology of nanoparticle agglomerates. The particles have different sizes with some roughness and spherical shape. Peppas model suggests for both systems, that the release mechanism is controlled by two parallel processes. The first one is by diffusion of the drug through the matrix and the second is related to a gradient of constant diffusion by ingress of the solvent in the matrix.


2007 ◽  
Vol 330-332 ◽  
pp. 1025-1028
Author(s):  
Shula Radin ◽  
T.L. Chen ◽  
Paul Ducheyne

Controlled release silica sol-gels are room temperature processed, porous, resorbable, and biocompatible materials. Many molecules including drugs, proteins, and growth factors can be released from sol-gels, and the quantity and duration of the release can vary widely. Processing parameters render these release properties exquisitely versatile [1]. The synthesis of controlled release sol-gels involves several steps: an acid-catalyzed hydrolysis to form a sol with the molecules included, followed by casting, aging, and drying. Additional steps such as grinding and sieving are required to produce sol-gel granules of a desirable size. In this study, we focus on the synthesis of controlled release sol-gel microspheres by using a novel process, which involves only two steps:sol formation followed by emulsification. Sol-gel microspheres containing either vancomycin (antibiotic) or bupivacaine (analgesic) were successfully synthesized via this synthesis route. Both drugs showed controlled, load-dependent and time-dependent release from the microspheres. The in vitro release properties of sol-gel microspheres were different from those of sol-gel granules produced by grinding and sieving. In comparison to a fast, short-term release from the granules, the release from the microspheres was slower and of longer duration. In addition, the degradation rate of microspheres was significantly slower than that of the granules. These data enable the use of sol-gel powders for controlled long-term release.


2003 ◽  
Vol 20 (5) ◽  
pp. 569-579 ◽  
Author(s):  
S.-A. Seo ◽  
G. Khang ◽  
J. M. Rhee ◽  
J. Kim ◽  
H. B. Lee

1987 ◽  
Vol 57 (02) ◽  
pp. 201-204 ◽  
Author(s):  
P Y Scarabin ◽  
L Strain ◽  
C A Ludlam ◽  
J Jones ◽  
E M Kohner

SummaryDuring the collection of samples for plasma β-thromboglobulin (β-TG) determination, it is well established that artificially high values can be observed due to in-vitro release. To estimate the reliability of a single β-TG measurement, blood samples were collected simultaneously from both arms on two separate occasions in 56 diabetic patients selected for a clinical trial. From each arm, blood was taken into two tubes containing an anticoagulant mixture with (tube A) and without (tube B) PGE!. The overall mean value of B-TG in tube B was 1.14 times higher than in tube A (p <0.01). The markedly large between-arms variation accounted for the most part of within-subject variation in both tubes and was significantly greater in tube B than in tube A. Based on the difference between B-TG values from both arms, the number of subjects with artifically high B-TG values was significantly higher in tube B than in tube A on each occasion (overall rate: 28% and 14% respectively). Estimate of between-occasions variation showed that B-TG levels were relatively stable for each subject between two occasions in each tube. It is concluded that the use of PGEi decreases falsely high B-TG levels, but a single measurement of B-TG does not provide a reliable estimate of the true B-TG value in vivo.


Sign in / Sign up

Export Citation Format

Share Document